Equities research analysts predict that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will report earnings of ($0.09) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics reported earnings of ($0.03) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 200%. The business is expected to announce its next earnings results on Thursday, March 29th.

According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.37) per share for the current year. For the next financial year, analysts expect that the business will report earnings of ($0.42) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. During the same quarter last year, the company posted ($0.09) EPS.

Separately, Maxim Group set a $9.00 price target on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 16th.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) remained flat at $$4.04 during mid-day trading on Friday. The company had a trading volume of 42,214 shares, compared to its average volume of 133,354. Brainstorm Cell Therapeutics has a 52 week low of $2.10 and a 52 week high of $5.18.

A number of institutional investors have recently added to or reduced their stakes in the business. Sphera Funds Management LTD. acquired a new position in Brainstorm Cell Therapeutics in the second quarter worth $2,759,000. Vanguard Group Inc. boosted its holdings in Brainstorm Cell Therapeutics by 2.8% in the second quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock worth $2,733,000 after purchasing an additional 17,657 shares during the period. Finally, KCG Holdings Inc. boosted its holdings in Brainstorm Cell Therapeutics by 4.6% in the first quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 1,820 shares during the period. 13.08% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://theolympiareport.com/2017/12/06/zacks-brokerages-expect-brainstorm-cell-therapeutics-inc-bcli-to-announce-0-09-eps.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.